Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02476019 · ClinicalTrials.gov registry record · Phase 2
A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT02476019 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 13 participants.
The verdict
NCT02476019, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-FGFR4RX.
Interventions
- DRUG Placebo
- DRUG ISIS-FGFR4RX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02476019
The ClinicalTrials.gov registry entry for NCT02476019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02476019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02476019 about?
NCT02476019 is a clinical study titled "A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients". The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-FGFR4RX.
What is the current status of trial NCT02476019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2015-06. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02476019?
The interventions under investigation include: Placebo (DRUG), ISIS-FGFR4RX (DRUG).
Who is sponsoring clinical trial NCT02476019?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.